ZimVie announced the U.S. launch of its GenTek Genuine Restorative Components product portfolio. The launch expands ZimVie’s portfolio of end-to-end prosthetic offerings and follows the recent receipt of FDA 510(k) clearance. ZimVie first launched the GenTek portfolio in Europe in 2019 and has seen tremendous success in that market to date. The introduction of GenTek to the U.S. market brings a broad offering of differentiated restorative components to the ZimVie product family. The GenTek restorative portfolio is comprised of Ti-Bases, pre-milled abutment blanks, screws, instruments, and ancillary products to support digitally driven CAD/CAM restorations.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZIMV:
- ZimVie Announces FDA Clearance and U.S. Launch of GenTek® Restorative Components
- ZimVie to Report Second Quarter Financial Results on August 1, 2024
- ZimVie jumps 15% to $21.70 after Bloomberg report of Osstem buyout talks
- Osstem Implant in advanced talks to buy ZimVie, Bloomberg reports
- ZimVie could be worth $25-$29 per share in takeout, says Needham